Search

Your search keyword '"Ramagopalan S"' showing total 19 results
Start Over Author "Ramagopalan S" Journal neurology
19 results on '"Ramagopalan S"'

4. Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene

Author

Dyment, D. A., primary, Cader, M. Z., additional, Chao, M. J., additional, Lincoln, M. R., additional, Morrison, K. M., additional, Disanto, G., additional, Morahan, J. M., additional, De Luca, G. C., additional, Sadovnick, A. D., additional, Lepage, P., additional, Montpetit, A., additional, Ebers, G. C., additional, and Ramagopalan, S. V., additional

Published
2012
Full Text
View/download PDF

10. HLA-DRB1 and month of birth in multiple sclerosis

Author

Ramagopalan, S. V., primary, Link, J., additional, Byrnes, J. K., additional, Dyment, D. A., additional, Giovannoni, G., additional, Hintzen, R. Q., additional, Sundqvist, E., additional, Kockum, I., additional, Smestad, C., additional, Lie, B. A., additional, Harbo, H. F., additional, Padyukov, L., additional, Alfredsson, L., additional, Olsson, T., additional, Sadovnick, A. D., additional, Hillert, J., additional, and Ebers, G. C., additional

Published
2009
Full Text
View/download PDF

18. HLA-DRB1*15 influences the development of brain tissue damage in early PPMS.

Author

Tur C, Ramagopalan S, Altmann DR, Bodini B, Cercignani M, Khaleeli Z, Miller DH, Thompson AJ, and Ciccarelli O

Subjects
Adult, Disease Progression, Female, Gray Matter pathology, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, White Matter pathology, Brain pathology, HLA-DRB1 Chains genetics, Multiple Sclerosis, Chronic Progressive genetics, Multiple Sclerosis, Chronic Progressive pathology, Spinal Cord pathology
Abstract

Objectives: To investigate whether (1) there were differences between HLA-DRB1*15-positive and -negative patients at baseline, and (2) HLA-DRB1*15-positive patients showed a greater development of brain and spinal cord damage, as assessed by MRI, and greater progression of disability, during a 5-year follow-up, compared with HLA-DRB1*15-negative patients., Methods: HLA-DRB1*15 typing was performed in 41 patients with primary progressive multiple sclerosis (PPMS) who were recruited within 5 years of symptom onset. All patients and 18 healthy controls were studied clinically and with MRI at baseline, and every 6 months for 3 years, and then at 5 years. Magnetization transfer ratio parameters and volumes for brain gray matter and normal-appearing white matter, brain T2 lesion load, and spinal cord cross-sectional area were obtained. Patient disability was assessed at each visit using the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite subscores., Results: There were no significant differences between HLA-DRB1*15-positive and -negative patients at baseline. HLA-DRB1*15-positive patients showed a greater decline in brain magnetization transfer ratio for gray matter and normal-appearing white matter (both p = 0.005) than HLA-DRB1*15-negative patients over 5 years, while the same parameters did not change over time in healthy controls. HLA-DRB1*15-positive patients also showed a trend toward a faster increase in brain T2 lesion load than HLA-DRB1*15-negative patients (0.29 [95% confidence interval 0.20-0.38] vs 0.21 [0.13-0.30] mL/mo, p = 0.085) and higher T2 lesion volumes at all time points (average difference [95% confidence interval]: 10.58 mL [7.09-14.07], p < 0.001) during the follow-up, after adjusting for disease duration., Conclusions: These findings suggest that HLA-DRB1*15 influences the progression of brain pathology in PPMS., (© 2014 American Academy of Neurology.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results